Nasal vaccines, or more accurately known as intranasal vaccines, can protect against airborne pathogens that enter through the nose causing the flu or the coronavirus. Research shows that delivering the vaccine directly to the mucosa might be a better approach for preventing Covid infection. Mayuresh Abhyankar, a researcher at the...
Codagenix, Inc., a clinical-stage biotechnology startup, has contracted with the Serum Institute of India to manufactuer CDX-005, the company's intranasal, live-attenuated vaccine candidate for SARS-CoV-2, the virus that causes COVID-19. Preclinical animal studies have been successfully completed, and the Long Island, New York company expects to initiate a Phase 1 first-in-human clinical trial in...
Codagenix, Inc., a clinical-stage biotechnology startup, has contracted with the Serum Institute of India to manufactuer CDX-005, the company's intranasal, live-attenuated vaccine candidate for SARS-CoV-2, the virus that causes COVID-19. Preclinical animal studies have been successfully completed, and the Long Island, New York company expects to initiate a Phase 1 first-in-human clinical trial in...